Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 19;7(1):7-9.
doi: 10.1002/ags3.12623. eCollection 2023 Jan.

Defining conversion therapy for esophageal squamous cell carcinoma

Satoru Matsuda  1 , Takahiro Tsushima  2 , Ken Kato  3 , Chih-Hung Hsu  4 , Jang Ming Lee  5 , Ian Yu-Hong Wong  6 , Hu-Lin Christina Wang  7 , Chang Hyun Kang  8 , Xufeng Guo  9 , Shun Yamamoto  3 , Takayuki Tsuji  1 , Hirofumi Kawakubo  1 , Hiroya Takeuchi  10 , Simon Law  6 , Yuko Kitagawa  1
Affiliations
Editorial

Defining conversion therapy for esophageal squamous cell carcinoma

Satoru Matsuda et al. Ann Gastroenterol Surg. .

Abstract

A multimodality treatment conference with experts from across East Asia was held to establish a consensus for conversion therapy. An agreement was reached that conversion therapy was defined as surgery or chemoradiotherapy (CRT) aiming at cure after initial treatment for tumors that were initially unresectable due to adjacent organ invasion or distant metastasis.

Keywords: conversion surgery; conversion therapy; esophageal squamous cell carcinoma.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Definition of conversion therapy for esophageal squamous cell carcinoma
See this image and copyright information in PMC

References

    1. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first‐line treatment of advanced oesophageal cancer (KEYNOTE‐590): a randomised, placebo‐controlled, phase 3 study. Lancet. 2021;398(10302):759–71. - PubMed
    1. Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous‐cell carcinoma. N Engl J Med. 2022;386(5):449–62. - PubMed
    1. Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO‐GC‐1). Ann Gastroenterol Surg. 2022;6(2):227–40. - PMC - PubMed
    1. Al‐Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO‐FLOT3 trial. JAMA Oncol. 2017;3(9):1237–44. - PMC - PubMed
    1. Terada M, Hara H, Daiko H, Mizusawa J, Kadota T, Hori K, et al. Phase III study of tri‐modality combination therapy with induction docetaxel plus cisplatin and 5‐fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous‐cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019;49(11):1055–60. - PubMed

Publication types